Automated On-Line Solid-Phase Extraction Coupled with HPLC for Measurement of 5-Hydroxyindole-3-acetic Acid in Urine

Erik J. Mulder,1 Alida Oosterloo-Duinkerken,2 George M. Anderson,3 Elisabeth G.E. De Vries,4 Ruud B. Minderaa,1 and Ido P. Kema2*

Background: Quantification of 5-hydroxyindole-3-acetic acid (5-HIAA) in urine is useful in diagnosing and monitoring of patients with carcinoid tumors and in the study of serotonin (5-hydroxytryptamine) metabolism in various disorders. We describe an automated method that incorporates on-line solid-phase extraction (SPE) and HPLC to measure urinary 5-HIAA.

Methods: Automated prepurification of urine was accomplished with HySphere-resin GP SPE cartridges containing strong hydrophobic polystyrene resin. The analyte (5-HIAA) and internal standard [5-hydroxyindole-3-carboxylic acid (5-HICA)] were eluted from the SPE cartridge, separated by reversed-phase HPLC, and detected fluorometrically with a total cycle time of 20 min. Urinary excretion of 5-HIAA was measured in a group of patients with known and suspected carcinoid tumors (n = 63) and in 20 patients with autism.

Results: The internal standard (5-HICA) and 5-HIAA were recovered in high yields (87.2%–114%). Within- and between-series CVs for the measurement of 5-HIAA in urine ranged from 1.2% to 3.9% and 3.2% to 7.6%, respectively. For urine samples from patients with known or suspected carcinoid tumors, results obtained by the automated method were highly correlated (r = 0.988) with those from an established manual extraction method. For samples from autistic patients, urinary excretion of 5-HIAA was similar to that reported for healthy individuals.

Conclusion: This SPE-HPLC method demonstrated lower imprecision and time per analysis than the manual solvent extraction method.

© 2005 American Association for Clinical Chemistry

The neurotransmitter/neurohormone serotonin [5-hydroxytryptamine (5-HT)]5 is synthesized from the essential amino acid tryptophan in the enterochromaffin cells of the gut and in serotonergic neurons in the central nervous system (1, 2). Peripheral serotonin is metabolized mainly in the lung and the liver through the action of monoamine oxidase-A. 5-Hydroxyindole-3-acetic acid (5-HIAA) is the predominant end-product of serotonin metabolism and is subsequently excreted in urine (3).

Serotonin is clearly involved in carcinoid syndrome and is hypothesized to play a role in schizophrenia, depression, migraine, and autism (4–6). The most pronounced deviations in serotonin metabolism are found in patients with carcinoid tumors, which can secrete large amounts of serotonin (7). Quantification of urinary 5-HIAA is important in the diagnosis and follow-up of such patients. Diagnosis can be established by measuring urinary 5-HIAA or platelet serotonin. When serotonin production of the tumor exceeds platelet storage capacity, however, changes in production will not be reflected in platelet serotonin concentrations, whereas changes in the amount of 5-HIAA excreted in urine will still occur (8). Increased platelet serotonin has also been observed in autistic patients, with typical reported group mean increases of 25%–50% (5). For the study of peripheral serotonin metabolism in autism, measurement of 5-HIAA in urine is useful to evaluate a possible role of altered

1 Child and Adolescent Psychiatry, 2 Department of Pathology and Laboratory Medicine, and 4 Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
3 Child Study Center, Yale University School of Medicine, New Haven, CT.
*Address correspondence to this author at: Department of Pathology and Laboratory Medicine, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. E-mail i.p.kema@lc.umcg.nl.
Received April 3, 2005; accepted June 23, 2005.
Previously published online at DOI: 10.1373/clinchem.2005.050062

5 Nonstandard abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); 5-HIAA, 5-hydroxyindole-3-acetic acid; SPE, solid-phase extraction; 5-HICA, 5-hydroxyindole-3-carboxylic acid; and CLSI, Clinical Laboratory Standards Institute.
production or catabolism in observed changes in platelet serotonin (5).

Since the early 1950s, many analytical methods have been described to measure 5-HIAA in urine (9). The first methods used colorimetric methodology, paper and thin-layer chromatography, or gas chromatography. Later, various HPLC analyses were reported that used colorimetric, fluorometric, or electrochemical detection (9). Recently, liquid chromatographic-tandem mass spectrometric methods have been reported for urine and whole blood (10, 11).

We developed an automated method with on-line solid-phase extraction (SPE) and HPLC with fluorometric detection to measure urinary 5-HIAA and applied this method to the determination of urinary 5-HIAA excretion rates in individuals with known or suspected carcinoid tumors and in individuals with autism.

**Materials and Methods**

**Reagents and Stock Solutions**

HPLC-grade acetonitrile and methanol were obtained from Rathburn; 5-HIAA and disodium EDTA were from Sigma; tetrabutylammonium bromide was from Romil; 5-hydroxyindole-3-carboxylic acid (5-HICA) was from Janssen Chimica; and acetic acid, sodium metabisulfite (Na2S2O5), ascorbic acid, phosphoric acid, potassium dihydrogen phosphate, and dipotassium hydrogen phosphate were from Merck. All reagents were of at least analytical reagent grade. Reagent-grade water, obtained from a Barnstead system, was used throughout.

Stock solutions containing 0.34 mmol/L 5-HICA or 2.1 mmol/L 5-HIAA were prepared in water containing 20 mL/L glacial acetic acid. The 5-HICA stock solution was stored protected from light at −20 °C for a maximum of 1 year. The 5-HIAA stock solution was prepared on the day of analysis. Saturated stock solutions containing ascorbic acid (300 g/L), dipotassium EDTA (750 g/L), and Na2S2O5 (750 g/L) were prepared in water and stored at room temperature for 3 weeks.

**Samples and Participants**

Patient urine samples were collected into brown polypropylene bottles (Sarstedt) containing ~250 mg each of Na2S2O5 and disodium EDTA. Urine samples were acidified to pH 4 with acetic acid and stored at −20 °C. Before analysis, aliquots of thawed urine samples (50 μL) were mixed with 300 μL of antioxidant solution (100 μL of ascorbic acid stock solution, 100 μL of dipotassium EDTA stock solution, and 100 μL of disodium EDTA stock solution) and 100 μL of internal standard stock solution (0.34 mmol/L 5-HICA). The mixture was then diluted with 1.2 mL of water, and 20 μL of each sample was injected into the SPE-HPLC system as described below. This injection volume was equivalent to 0.61 μL of urine.

For method-comparison studies, we used spot urine samples from 63 patients with suspected or known carcinoid tumors and 24-h urine specimens from 20 individuals with autism (12).

**Analysis and Quantification**

**Instrumentation.** The Prospekt-2 (Spark Holland) on-line SPE unit consisted of 3 modules: an SPE controller unit (automated cartridge exchanger), a solvent delivery unit (high-pressure dispenser), and an autosampler (Triathlon). A SparkLink software package (Ver. 2.10) was required for control of the Prospekt-2 modules. The main task of the automated cartridge exchangers was exchange of disposable SPE cartridges. The high-pressure dispenser had a single-syringe configuration and delivered solvents for conditioning, sample application, and clean up of SPE cartridges. HySphere-resin GP cartridges (10 × 2 mm;
Spark Holland) were used for cleaning up samples and concentrating analytes. Samples were injected with a Triathlon autosampler. The HPLC pump used was a Gynkotek Series P580A binary high-pressure gradient pump (Softron); detection was with a Waters 474 spectrofluorometer (excitation wavelength, 280 nm; emission wavelength, 360 nm). The temperature of the column was regulated with a Mistral column oven (Spark Holland).

For analytical HPLC, a 100 × 4.6 (i.d.) mm Brownlee Spheri-5 RP-18 column filled with 5-μm spherical particles (Inacom) was used. The analytical column was preceded by a 15 × 3.2 (i.d.) mm Aquapore RP18 ODS guard column filled with 7-μm spherical particles (Inacom). Detector output was integrated by ChromPerfect (Ver. 3.51) integration software (Justice Innovations).

**Eluents.** The isocratic system consisted of eluent B (11 mmol/L dipotassium hydrogen phosphate and 3 mmol/L tetrabutylammonium bromide in water adjusted to pH 6.0 with phosphoric acid, added to 80 mL of acetonitrile to a total eluent volume of 1 L). Eluent A (22 mmol/L potassium dihydrogen phosphate in water adjusted to pH 2.0 with phosphoric acid, added to 10 mL of acetonitrile to a total eluent volume of 1 L) was delivered to the high-pressure dispenser.

Before use, eluent B was filtered through a 0.45 μm membrane filter (Schleicher & Schuell) and was degassed before entering the HPLC pump. The flow rate of eluent B was 1.0 mL/min, and chromatography was performed at 20 °C.

**On-line SPE.** On-line SPE was performed according to the schedule specified in Table 1 and as depicted schematically in Fig. 1. The system was designed to proceed automatically through a series of programmable routines during which the SPE cartridge was loaded, purged for clean up, and eluted to the analytical column. During the loading routine, the SPE cartridge was conditioned sequentially with methanol, eluent A, 5 g/L dipotassium EDTA in water, and eluent A, all provided by the high-pressure dispenser. The mixing coil between the high-pressure dispenser and the autosampler facilitated mixing of the eluents before they reached the cartridge.

After the mixed eluents reached the cartridge, the autosampler injected the sample, thereby loading the cartridge with the sample, using eluent A. The high-pressure dispenser then continued to wash the loaded cartridge with eluent B, thus cleaning the cartridge; the analytes were then eluted from the cartridge to the analytical column with eluent B in 1.5 min. After elution from the cartridge, chromatographic separation on the analytical column occurred. During this separation, the next sample was loaded on the cartridge and washed. When the pump was ready, this sample was eluted to the analytical column. If necessary, cartridges could be changed automatically.

5-HIAA was quantified by calculation of the peak-area ratios in samples relative to those of the internal standard (5-HICA). Sample peak-area ratios were compared with the peak-area ratios obtained for the calibration solutions.
at 6 different concentrations, which were prepared by addition of known amounts of 0.21 mmol/L 5-HIAA calibrator solution (prepared fresh daily by diluting the stock solution 10-fold with water).

Urine creatinine was measured by a picric acid method on a Merck Mega Analyzer.

**ANALYTICAL CHARACTERISTICS**

In on-line SPE, detection limits depend on the extent of sample preconcentration on the SPE cartridge. For urine, we determined detection limits by injecting samples with decreasing concentrations of 5-HIAA. The detection limit was defined as the injected amount that produced a signal-to-noise ratio of 3. We estimated the percentage of carryover between sequential analyses performed on a single SPE cartridge by alternating injections of blanks and urine samples with high concentrations of 5-HIAA.

![Fig. 2](image-url)

**Fig. 2.** Chromatograms of urine from a healthy adult and a patient with carcinoid tumor, as obtained by on-line SPE coupled to HPLC with fluorescence detection.

Excitation wavelength, 280 nm; emission wavelength, 360 nm. (A), separation of 5-HIAA and the internal standard 5-HICA (injected amounts, 0.34 nmol for both). (B), 5-HIAA in urine from a healthy adult (note the 10-fold increase in sensitivity). (C), 5-HIAA in urine obtained from a patient with carcinoid tumor. Chromatograms in B and C were obtained with 20 μL injections of diluted urine (equivalent to 0.61 μL of urine). Calculated 5-HIAA concentrations in the urine samples were 8.75 and 506 μmol/L for B and C, respectively.

**QUALITY CONTROL AND VALIDATION OF THE AUTOMATED URINARY 5-HIAA METHOD**

Recoveries were estimated by the addition of 5-HIAA in 3 different concentrations (160, 350, and 520 μmol/L) to 1 urine specimen. Recoveries were measured in 6 replicates of these samples and calculated relative to the recovery of the internal standard; mean recoveries and ranges are reported. Within- and between-series precision was determined by use of 3 samples with 5-HIAA concentrations in the low, medium, and high ranges. Within-series precision was assessed in 6 replicates analyzed in a single series; between-series precision was assessed on 6 different days over a 1-month period. Experiments were performed using 1 SPE cartridge per series.

The identities of sample 5-HIAA peaks were verified by addition of calibrator (standard addition) and by

![Fig. 3](image-url)

**Fig. 3.** Comparison of 5-HIAA results for 63 urine samples as derived from the automated SPE-HPLC method (y axis) and the ether extraction method (x axis).

The main panel shows values from 0 to 100 μmol/L. Equation for the line: \( y = 0.996x - 3.50 \) μmol/L (r = 0.998; P < 0.0001). The inset shows values from 100 to 1500 μmol/L.
observation of retention time changes of the sample peak under different chromatographic conditions. The automated urinary 5-HIAA method was also validated by comparison of its results with those obtained by our routinely used manual ether extraction method (13).

Statistics
We compared methods by Deming regression analysis using the slope and intercept; we also calculated the correlation coefficient and the standard error of prediction \((S_{xy})\). The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS) EP-6P protocol (14) was applied to test the linearity of the method.

Results
Chromatography
The chromatographic separation of 2 calibrators by automated on-line SPE and HPLC with fluorometric detection is shown in Fig. 2A. Total cycle time was ~20 min (Table 1). Chromatograms of urine samples obtained from a healthy adult and from a patient with a carcinoid tumor are shown in panels B and C, respectively, of Fig. 2 (note the different sensitivity scales). Complete separation of the analytes from interferents was achieved within 16 min. Comparison of the 2 chromatograms shows markedly increased 5-HIAA in the sample from the patient.

Analytical Characteristics
A signal-to-noise ratio of 3 was achieved at a 5-HIAA concentration of 0.8 \(\mu\)mol/L. Analysis of a split urine specimen with increasing amounts of added 5-HIAA calibrator demonstrated that the assay was linear to 5-HIAA concentrations of at least 2000 \(\mu\)mol/L. The percentage carryover between sequential analyses performed on a single SPE cartridge was <1%.

Quality Control and Validation of the Automated Urinary 5-HIAA Method
The results of the recovery and precision experiments are presented in Table 2. The recovery data represent recoveries for 6 replicates of each of 3 samples analyzed in 1 analysis time series with 1 SPE cartridge. Recoveries ranged from 87.2% to 114.0%. Within-series imprecision (as CVs) based on 6 measurements of 3 different urine samples were 3.9%, 1.6%, and 1.2% in samples with mean (SD) 5-HIAA concentrations of 2.3 (0.1), 25.0 (0.4), and 147.9 (1.7) \(\mu\)mol/L, respectively. The between-series imprecision (CVs) for analyses performed across 6 series were 7.6%, 3.7%, and 3.2% in samples with 5-HIAA concentrations of 2.5 (0.2), 26.3 (1.0), and 154.8 (3.2) \(\mu\)mol/L, respectively.

As seen in Fig. 3, 5-HIAA values determined in 63 clinical samples by the automated SPE method were highly correlated with results obtained by the manual ether extraction method (13). Deming regression gave a slope of 0.9996 (range, 0.9811–1.0181) and a \(y\)-intercept of \(-3.50 \mu\)mol/L (95% confidence interval, \(-9.92 \text{ to } 2.92 \mu\)mol/L). The Spearman correlation coefficient was 0.988 \((P < 0.0001)\), and the SE of prediction \((S_{xy})\) was 3.21 \(\mu\)mol/L. The lack of linear fit test according to the CLSI EP-6P protocol indicated no significant deviance from linearity \((F = 0.22; P = 0.80)\).

In the autism group, mean (SD) 24-h urinary 5-HIAA excretion [0.0165 (0.0086) mmol/24 h or 1.74 (0.79) mmol/mol creatinine] was similar to that reported previously for control groups and autistic patients (9, 15–17).

Discussion
A variety of methods for urine 5-HIAA analysis have been described, including several HPLC methods (9). The automated SPE-HPLC method we developed reduced the per sample analysis time considerably, with a concomitant increase in sample throughput. The CVs for this method were ~50% lower than those for the manual method. We found that use of the on-line SPE system allows regeneration of SPE cartridges up to 40 times when small amounts of urine or plasma are extracted (18). This can be done with negligible loss of accuracy. During the 2-year period that this method has been in operation, interferences from drugs and other substances have been extremely rare (and discernable). The group mean urine concentrations and excretion rates reported here for 5-HIAA were within the reference intervals established at the University Hospital Groningen and were in excellent agreement with previous reports (9, 15–17).

In summary, our automated SPE-HPLC method for the determination of urinary 5-HIAA appears to offer advantages in time and precision compared with manual chromatographic methods.

References


